Len Schleifer made something of a splash at an industry conference last December. The Regeneron Pharmaceuticals chief executive chastised Pfizer chief executive Ian Read over drug prices while participating in a panel discussion. Not surprisingly, their exchange received notice, since pricing is such a hot-button issue. Schleifer remains adamant, though, that brand-name drug makers can do better and he hopes to prove the point when his company launches a medicine for severe eczema. We recently spoke with him about drug pricing and the FDA, too. This is an excerpt.

Pharmalot: You made a point that companies shouldn’t be doing things like taking more than one price hike a year or a certain percentage. But what, if any, commitment has your company made or is willing to make?

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X